
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
An app that tracks cigarette cravings and moods, one that guides patients through proper inhaler use, and 3 other top COPD apps for both patients and physicians.






